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Abstract
Background: We sought to evaluate prognostic factors affecting overall survival (OS), and to investigate the role of
palliative chemotherapy using propensity score-based weighting, in patients with advanced small bowel
adenocarcinoma (SBA).
Methods: Data from a total of 91 patients diagnosed with advanced SBA at the Asan Medical Center between
January 1989 and December 2009 were retrospectively analyzed. Patients were split into two groups, those who
did and did not receive palliative chemotherapy.
Results: Overall, 81 patients (89.0%) died, at a median survival time of 6.6 months (95% confidence interval [CI],
5.5 - 7.5 months). The 40 patients receiving chemotherapy showed overall response and disease control rates of
11.1% and 37.0%, respectively, with OS and progression-free survival (PFS) of 11.8 months (95% CI, 4.6 - 19.0 months)
and 5.7 months (95% CI, 3.5 - 8.0 months), respectively. The 41 patients who did not receive chemotherapy had an
OS of 4.1 months (95% CI, 3.1 - 5.1 months) and a PFS of 1.3 months (95% CI, 0.8 - 1.7 months). Multivariate analysis
showed that lack of tumor resection, non-prescription of chemotherapy, liver metastasis, and intra-abdominal lymph
node metastasis, were all independently associated with poor survival outcomes. After inverse probability of
treatment weighting (IPTW) adjustment, the group that did not receive chemotherapy was at a significantly higher
risk of mortality (HR 3.44, 95% CI 2.03 - 5.83, p < 0.001) than were patients receiving chemotherapy.
Conclusion: Palliative chemotherapy may improve survival outcomes in patients with advanced SBA.
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Background
Small bowel cancer is very rare, accounting for 0.46% of
all malignancies in the United States and 0.35% in South
Korea [1,2]. Adenocarcinoma of the small bowel (SBA)
is the most common histological type of such cancer,
constituting 35.8% of small bowel malignancies [3].
Although patients with SBA have poor prognosis, few
reliable data are available because of the rarity of such
tumors. The treatment of choice for SBA is curative sur-
gical resection. However, no standard protocol has been
defined for use when SBA relapses or is unresectable
because of locally advanced or metastatic status.
Although several retrospective analyses have found that
chemotherapy offers survival benefits in such patients,
no prospective study has compared palliative che-
motherapy with supportive care [4].
Propensity score-based weighting is a rigorous statisti-
cal technique permitting nonrandomized comparisons,
and theoretically permits all data from two groups of
patients to be used [5]. We employed this method to
adjust for selection differences between patients with
advanced BSA who received either palliative chemother-
apy or supportive care, and we compared survival out-
comes in two groups adjusted in such a manner. Thus,
propensity score-based weighting allowed us to evaluate
prognostic factors affecting overall survival (OS) in
* Correspondence: twkimmd@amc.seoul.kr
1Department of Oncology, University of Ulsan College of Medicine, Asan
Medical Center, Seoul, Korea
Full list of author information is available at the end of the article
Koo et al. BMC Cancer 2011, 11:205
http://www.biomedcentral.com/1471-2407/11/205
© 2011 Koo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.patients with advanced SBA, and to explore the role
played by palliative chemotherapy in treatment of the
disease.
Materials & methods
We searched the Asan Medical Center Cancer Database
to identify all patients who had been diagnosed with
SBA at the Asan Medical Center (Seoul, Korea) between
January 1989 and December 2009. Patients were
included if they were ≥ 18 years of age; had histologi-
cally confirmed SBA with documentation of locally
advanced, recurrent, or metastatic disease; and had no
history of other malignancies. Patients with cancer of
the ampulla of Vater or periampullary cancer were
excluded. Of the 238 patients screened, 91 fulfilled all
inclusion criteria. Patients with ampulla of Vater and
peri-ampullary cancer (110 patients) and initially resect-
able disease (37) were excluded. Patients were divided
into two groups, those who did or did not receive pallia-
tive chemotherapy. Patient medical records were
reviewed to extract demographic data, tumor character-
istics, type of treatment, response to treatment, and sur-
vival information. The protocol of this retrospective
study was approved by the Institutional Review Board of
the Asan Medical Center.
The primary endpoint of the study was OS. Secondary
endpoints in the chemotherapy group were progression-
free survival (PFS) and response rate (RR). OS was mea-
sured from the date of diagnosed advanced SBA, or con-
firmed recurrence, to the day of death from any cause,
or was censored at last follow-up. PFS was measured
from the date on which chemotherapy commenced to
the day on which tumor progression or death from any
cause was noted, or was censored at last follow-up. Sur-
vival curves were constructed using the Kaplan-Meier
method and compared using the log-rank approach.
Multivariate analysis defining factors associated with
survival utilized a stepwise Cox’sp r o p o r t i o n a lh a z a r d
regression model. Differences in baseline characteristics
between patients who did and did not receive systemic
chemotherapy were compared using the t-test or the
Mann-Whitney test for continuous variables, and the c2
test or Fisher’s exact test for categorical variables, as
appropriate. To reduce the impact of treatment selection
bias and potential confounding in this observational
study, we used weighted Cox’s proportional hazards
regression models to adjust for significant differences in
patient characteristics, using inverse probability of treat-
ment weighting (IPTW) and robust standard errors [6].
Weights for patients receiving chemotherapy were the
inverse of the [1-propensity score] values, and the
weight for each patient not receiving chemotherapy was
the inverse of the propensity score. All propensity scores
were estimated without regard to outcomes, using
multiple logistic regression analysis. A full model
included the following factors: age, gender, primary
tumor site, tumor histology, initial status, previous
tumor resection, number of metastasis sites, liver metas-
tasis status, peritoneal metastasis status, presence or
absence of intra-abdominal lymph node (IALN) metasta-
sis, lung metastasis status, presence or absence of bone
metastasis, and Eastern Cooperative Oncology Group
(ECOG) performance status (PS). Model discrimination
was assessed using c-statistics (c = 0.786), and model cali-
bration was evaluated employing the Hosmer-Lemeshow
goodness-of-fit test (c2 = 2.282, df = 8, p = 0.9711). A
two-sided p value < 0.05 was considered significant, and
95% confidence intervals (CIs) were also calculated. All
statistical analyses were performed using SPSS software
(SPSS Inc., Chicago, IL).
Results
A total of 91 patients, of median age 58 years (range, 25-
82 years), were followed-up for a median time of 10.0
months (range, 4.4 - 26.4 months). Overall, 81 patients
(89.0%) died, with a median survival time of 6.6 months
(95% CI, 5.5 - 7.5 months; Figure 1). At the time of
diagnosis, 54 patients (59.3%) had ECOG PS of 0 to 1.
A comparison of baseline characteristics is shown in
Table 1. Patients in the chemotherapy group were signifi-
cantly younger, and a significantly higher percentage had
undergone resection of primary tumors. In contrast,
higher proportions of patients in the non-chemotherapy
group had IALN metastasis and poor PS. Of the 22
patients in the non-chemotherapy group who had good
PS (0-1), 9 (40.0%) underwent bypass surgery, 2 (10.0%)
palliative resection, and 1 (5.0%) stent insertion, whereas
10 (45.0%) received no treatment. Twenty of the
Figure 1 Overall survival (OS) curves of all patients and of
those receiving or not receiving chemotherapy (CTx).
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Page 2 of 622 patients (91%) with good PS did not receive che-
motherapy because of patient refusal, whereas 1 (5.0%)
patient could not be treated because of the presence of
pancreatitis, and 1 (5.0%) further patient did not receive
chemotherapy because post-operative radiotherapy was
prescribed.
The chemotherapy regimens were based on fluoropyri-
midine. Of the 40 patients who received chemotherapy,
25 (62.5%) were prescribed fluoropyrimidine and plati-
num, including 12 who received standard FP and 13 who
took capecitabine-plus-cisplatin. Seven patients (17.5%)
received oral fluoropyrimidine; three (7.5%) 5-FU plus
leucovorin; and three (7.5%) fluoropyrimidine and irino-
tecan (FOLFIRI), whereas two (5.0%) received fluoropyri-
midine, adriamycin, and mitomycin. The median number
of chemotherapy cycles was 4 (range, 1-26 cycles). The
overall response rate for the 27 patients with measurable
lesions was 11.1%, with 3 patients showing partial
responses, and the disease control rate was 37.0%, with 7
patients showing stable disease. OS and PFS were 11.8
months (95% CI, 4.6 - 19.0 months) and 5.7 months (95%
CI, 3.5 - 8.0 months), respectively (Figure 2). In contrast,
the OS and PFS of patients not receiving chemotherapy
w e r e4 . 1m o n t h s( 9 5 %C I ,3 . 1-5 . 1m o n t h s )a n d1 . 3
months (95% CI, 0.8 - 1.7 months), respectively.
In univariate analysis, the following factors were sig-
nificantly associated with poor survival outcome: ECOG
Table 1 Pretreatment patient characteristics
All patients Palliative Chemotherapy No Chemotherapy p value
n=9 1 n=4 0 n=5 1
Age (years) Median (range) 58 (25 - 82) 55 (25 - 74) 59 (34 - 82) 0.03
Gender Male 67 (73.6%) 31 (77.5%) 36 (70.6%) 0.46
ECOG PS 0/1 54 (59.3%) 32 (80.0%) 22 (43.1%) <0.01
2/3 33 (36.3%) 8 (20.0%) 25 (49.0%)
NA 4 (4.4%) 0 (0.0%) 4 (7.8%)
Primary cancer site Duodenum 71 (78.0%) 28 (70.0%) 43 (84.3%) 0.10
Jejunoileum 20 (22.0%) 12 (30.0%) 8 (15.7%)
Histology WD/MD 44 (48.4%) 18 (45.0%) 26 (51.0%) 0.57
Undifferentiated 38 (41.8%) 19 (47.5%) 19 (37.3%)
Undetermined 9 (9.8%) 3 (7.5%) 6 (11.8%)
Status Recurrent 17 (18.7%) 11 (27.5%) 6 (11.8%) 0.15
Locally advanced 4 (4.4%) 2 (5.0%) 2 (3.9%)
Metastatic 70 (76.9%) 27 (67.5%) 43 (84.3%)
Primary tumor Resected 29 (31.9%) 19 (47.5%) 10 (19.6%) <0.01
Still present 62 (68.1%) 21 (52.5%) 41 (80.4%)
Number of metastasis 0 4 (4.4%) 2 (5.0%) 2 (3.9%) 0.62
1 50 (54.9%) 24 (60.0%) 26 (51.0%)
≥2 37 (40.7%) 14 (35.0%) 23 (45.1%)
Liver metastasis Yes 39 (42.9%) 14 (35.0%) 25 (49.0%) 0.18
Peritoneal metastasis Yes 42 (46.2%) 19 (47.5%) 23 (45.1%) 0.82
IALN metastasis Yes 41 (45.1%) 13 (32.5%) 28 (54.9%) 0.03
Lung metastasis Yes 6 (6.6%) 2 (5.0%) 4 (7.8%) 0.59
Bone metastasis Yes 3 (3.3%) 2 (5.0%) 1 (2.0%) 0.42
Treatment interval 1989-1999 25 (27.5%) 10 (25.0%) 15 (29.4%) 0.64
2000-2009 66 (72.5%) 30 (75.0%) 36 (70.6%)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NA, not available; WD, well-differentiated; MD, moderately differentiated; IALN,
intra-abdominal lymph node.
Figure 2 Overall survival (OS) and progression-free survival
(PFS) curves of patients receiving chemotherapy
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Page 3 of 6PS ≥ 2, duodenum as the primary tumor site, no pre-
vious tumor resection, liver metastasis, peritoneal metas-
tasis, IALN metastasis, and absence of chemotherapy
(Table 2). Upon subsequent multivariate analysis, four
factors were independently associated with poor survival
outcome: absence of tumor resection, liver metastasis,
IALN metastasis, and absence of chemotherapy (Table
3).
Because the factor “no chemotherapy” showed the
highest hazard ratio upon multivariate analysis (HR =
3.34), we evaluated the effect of chemotherapy on OS
after adjusting for differences in patient characteristics
between those in the chemotherapy and non-che-
motherapy groups (please see Methods). After IPTW
adjustment, non-chemotherapy group patients were at a
significantly higher risk of mortality (HR 3.44, 95% CI
2.03 - 5.83, p < 0.001) than were those in the che-
motherapy group. Further, of all factors analyzed, the
absence of chemotherapy significantly affected OS, con-
sistent with the data of the IPTW model (HR range,
2.61 - 13.49; Table 4; Figure 3).
Discussion
We found that the factors independently prognostic of
poor OS in patients with advanced SBA were absence of
chemotherapy, no prior tumor resection, liver metasta-
sis, and IALN metastasis. After adjustment of clinical
factors using the IPTW method, chemotherapy status
remained significantly associated with OS.
Of the four factors independently predictive of poor
prognosis, three have previously been identified in
patients with advanced SBA; these are absence of che-
motherapy [7,8], no prior tumor resection [8-11], and
liver metastasis [11]. The tumor burden of patients
experiencing recurrence after curative resection, or
metastasis after palliative resection has been regarded as
lower than the burden in patients who did not undergo
surgical resection. Although duodenal tumor location
and peritoneal seeding have been reported to be predic-
tive of poor prognosis in other series [7,10-12], they
were not statistically significant in our analysis.
In agreement with previous retrospective studies, our
findings suggest that palliative chemotherapy may bene-
fit patients with SBA [7,9,13-16]. As patients who did
not receive chemotherapy showed the poorest prognosis,
we sought to estimate the effects of chemotherapy. In
principle, the best way to evaluate the efficacy of a treat-
ment is to employ a prospective randomized comparison
study, but this is near-impossible because of the rarity of
SBA. Therefore, the clinical backgrounds of patients in
each group were adjusted using propensity scoring, to
minimize selection bias, and the survival of patients in
the chemotherapy and non-chemotherapy groups was
compared. As we could not perform analyses using
score-matched pairs, because of the small sample size,
we utilized the IPTW method to show that chemother-
apy could significantly improve OS in patients with
advanced SBA.
The response rate (11%) and survival outcome (med-
ian OS, 11.8 months) observed in patients receiving che-
motherapy were comparable to those previously
reported [9,10,12,13,15-18]. However, an optimal che-
motherapy regimen remains to be defined. Chemother-
apy in patients with SBA is guided primarily by the
treatment of patients with colorectal or upper gastroin-
testinal tract cancers. FOLFOX has been shown to
Table 2 Univariate analysis of factors affecting survival
Factor Category Event Median
OS
95% CI p
value
Age (years) <58 44 6.7 m 6.0 - 7.4 0.41
≥58 47 6.2 m 3.2 - 9.3
Gender Male 67 6.6 m 5.7 - 7.5 0.83
Female 24 6.4 m 2.5 - 10.4
ECOG PS 0/1 54 7.2 m 6.0 - 8.4 <0.01
2/3 33 4.5 m 3.3 - 5.7
NA 4 2.6 m 0.0 - 6.9
Primary site Duodenum 71 6.2 m 5.0 - 7.5 <0.01
Jejunoileum 20 11.9 m 5.1 - 18.6
Histology WD/MD 44 6.8 m 6.2 - 7.3 0.45
Undifferentiated 38 5.1 m 2.3 - 7.9
Undetermined 9 8.3 m 0.1 - 16.6
Initial status Recurrent 17 10.5 m 4.0 - 17.1 0.21
Locally
advanced
4 6.8 m 5.9 - 7.8
Metastatic 70 5.8 m 4.3 - 7.4
Primary tumor Resected 29 11.8 m 3.8 - 19.8 <0.01
Still present 62 5.2 m 3.5 - 6.8
Number of
metastasis
0 4 6.8 m 5.9 - 7.8 0.20
1 50 7.1 m 5.8 - 8.4
≥2 37 5.5 m 2.7 - 8.3
Liver metastasis Yes 39 4.2 m 3.6 - 4.8 <0.01
No 52 7.8 m 6.3 - 9.3
Peritoneal
metastasis
Yes 42 5.9 m 3.7 - 8.0 0.03
No 49 8.6 m 5.5 - 11.8
IALN metastasis Yes 41 5.5 m 3.6 - 7.4 <0.01
No 50 7.7 m 6.8 - 8.6
Lung
metastasis
Yes 6 3.1 m 0.0 - 6.9 0.14
No 85 6.7 m 5.6 - 7.8
Bone
metastasis
Yes 3 5.2 m 2.4 - 7.9 0.75
No 88 6.6 m 5.7 - 7.5
Chemotherapy (+) 40 11.8 m 4.6 - 19.0 <0.01
(-) 51 4.1 m 3.1 - 5.1
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance
Status; NA, not available; WD, well-differentiated; MD, moderately
differentiated; IALN, intra-abdominal lymph node.
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platin [11]. A recent prospective Phase II trial of capeci-
tabine-plus-oxaliplatin in patients with advanced SBA
and ampullary adenocarcinoma yielded an overall RR of
50%, a median time-to-progression of 11.3 months, and
a median OS of 20.4 months [19].
Our results should be interpreted with caution
because this study had several limitations including its
retrospective design and patients from a single institu-
tion, which could have selection biases. Bone and lung
metastasis could be underestimated because bone scan
and chest CT were not mandatory for the evaluation of
disease extent. Furthermore, chemotherapy treatments
were not homogeneous even though the majority of
regimens consisted of fluoropyrimidine-based che-
motherapy. Nonetheless, it should be considered that
our cohort is one of the largest advanced SBA group
evaluated to date.
Table 3 Multivariate analysis of factors affecting survival.
HR 95% CI p value
Chemotherapy Not given 3.34 1.76 - 5.60 <0.001
Liver metastasis Yes 2.43 1.51 - 3.91 <0.001
Primary tumor Not resected 2.44 1.30 - 4.57 0.006
IALN metastasis Yes 1.65 1.02 - 2.67 0.042
Primary site Duodenum 1.19 0.55 - 2.56 0.986
Peritoneal metastasis Yes 1.49 0.91 - 2.46 0.116
ECOG PS 2/3 1.03 0.61 - 1.75 0.807
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance
Status; IALN, intra-abdominal lymph node.
Table 4 Effects of chemotherapy on overall survival (OS)
of various patient subsets.
Factors N HR 95% CI p
value
After IPTW All factors 91 3.44 2.03 - 5.83 <0.001
Age (years) <58 44 2.93 1.46 - 5.85 0.002
≥58 47 8.10 3.17 - 20.67 <0.001
Gender Male 67 4.97 2.69 - 9.18 <0.001
Female 24 3.47 1.19 - 10.13 0.023
ECOG PS 0/1 54 3.93 2.03 - 7.63 <0.001
≥ 2 33 4.55 1.64 - 12.65 0.004
Primary site Duodenum 71 3.10 1.76 - 5.44 <0.001
Jejunoileum* 20 NA 0.122
Histology WD/MD 44 7.63 3.01 - 19.36 <0.001
Undifferentiated 38 2.76 1.35 - 5.66 0.006
Status Recurrent 17 7.33 1.64 - 32.75 0.009
Metastatic 70 3.97 2.17 - 7.27 <0.001
Primary tumor Resected 29 13.49 3.48 - 52.36 <0.001
Still present 62 2.61 1.44 - 4.75 0.002
No. of Metastases 1 50 6.13 2.96 - 12.71 <0.001
>1 37 3.21 1.40 - 7.38 0.006
Liver metastasis Yes 39 4.29 1.65 - 9.43 <0.001
No 52 5.34 2.52 - 11.31 <0.001
Peritoneal
metastasis
Yes 42 7.37 2.98 - 18.27 <0.001
No 49 3.16 1.64 - 6.09 0.001
IALN metastasis Yes 41 3.06 1.36 - 6.89 0.007
No 50 5.22 2.56 - 10.65 <0.001
Lung metastasis Yes 6 NA 0.486
No 85 4.53 2.62 - 7.82 <0.001
Bone metastasis Yes 3 NA 0.809
No 88 4.6 2.78 - 7.92 <0.001
* Deaths: 8/8 in the patient group not receiving chemotherapy; 7/12 in the
patient group treated with chemotherapy.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance
Status; NA, not available; WD, well-differentiated; MD, moderately
differentiated; IALN, intra-abdominal lymph node.
Figure 3 The effect of chemotherapy on subset analyses of
overall survival (OS), with hazard ratios and 95% CI values for
OS
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In conclusion, we identified four factors predictive of
poor prognosis in patients with advanced small bowel
adenocarcinoma. After IPTW adjustment, using propen-
sity scoring to reduce selection bias, we found that
patients who did not receive chemotherapy were at a
significantly higher risk of mortality. Our findings indi-
cate that chemotherapy may improve survival outcomes
in patients with advanced SBA.
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